Crossref
Perspectives on Follicular Lymphoma Treatment From New and Experienced Clinicians: New, Old, & Old Is New.
ONCOLOGY · 2022
DOI: 10.46883/2022.25920947 ↗Kurz gefasst
Fachartikel in der Zeitschrift ONCOLOGY, 2022. Verfasst von Jonathan R Day und 1 weiteren Autor:innen. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalHumansImmunotherapy, AdoptiveLymphoma, FollicularMolecular Targeted TherapyProtein Kinase Inhibitors
Substanzen
Antibodies, MonoclonalAntineoplastic Agents, ImmunologicalProtein Kinase Inhibitors
Förderung
- NHLBI NIH HHS
Zitieren
APA
Day, J. R., & Link, B. K. (2022). Perspectives on Follicular Lymphoma Treatment From New and Experienced Clinicians: New, Old, & Old Is New. ONCOLOGY. https://doi.org/10.46883/2022.25920947
Vancouver
Day JR, Link BK. Perspectives on Follicular Lymphoma Treatment From New and Experienced Clinicians: New, Old, & Old Is New. ONCOLOGY. 2022. doi:10.46883/2022.25920947
BibTeX
@article{Day2022,
author = {Day, Jonathan R and Link, Brian K},
title = {Perspectives on Follicular Lymphoma Treatment From New and Experienced Clinicians: New, Old, & Old Is New},
journal = {ONCOLOGY},
year = {2022},
doi = {10.46883/2022.25920947}
}
EUVIMED